**DESCRIPTION**

**Species Reactivity**: Human

**Specificity**: Detects human vWF-A2 (ADAMTS13-cleaved) in Western blots. This antibody detects a nascent epitope that is generated upon cleavage of recombinant human (rh) vWF-A2 domain with ADAMTS13. It does not detect intact rhvWF-A2 domain.

**Source**: Monoclonal Mouse IgG1 Clone # 490628

**Purification**: Protein A or G purified from hybridoma culture supernatant

**Immunogen**: KLH-conjugated human vWF synthetic peptide Asp1596-Tyr1605 Accession # NP_000543

**Formulation**: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl with Trehalose. See Certificate of Analysis for details.

*Small pack size (SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.

**APPLICATIONS**

**Please Note**: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Recommended Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western Blot</td>
<td>1 µg/mL</td>
</tr>
</tbody>
</table>

Recombinant Human vWF-A2 (Catalog # 2764-WF) cleaved with Recombinant Human ADAMTS13 (Catalog # 4245-AD)

**PREPARATION AND STORAGE**

**Reconstitution**: Reconstitute at 0.5 mg/mL in sterile PBS.

**Shipping**: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C.

**Stability & Storage**: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

**BACKGROUND**

von Willebrand Factor (vWF) is a large, multimeric glycoprotein made by endothelial cells and megakaryocytes. The pre-pro-vWF protein contains 2813 amino acids (aa), which consists of 22 aa signal peptide, 741 aa propeptide, and mature vWF monomer of 2050 aa (1-4). The pro-vWF undergoes dimerization in the endoplasmic reticulum (ER) through C-terminal "cysteine-knot" (CK) domain. The pro-vWF dimmers are transported to Golgi and form multimers by forming disulfide bond in amino-terminal region of the mature form. The proteolytic processing of pro-region also occurs in Golgi. The mature vWF is stored in Weibel-Pallade bodies in endothelial cells and granules in megakaryocytes and platelets. The unusually-large vWF (ulvWF) multimers released from cells are very efficient in binding to platelets to form thrombus. The population of these highly active ulvWF multimers is controlled by a specific protease, ADAMTS13, which cleaves between residues Tyr1605 and Met1606 in the A2 domain of vWF. In the plasma, vWF appears as a series of large and intermediate multimers with molecular masses from several thousand to 500 kDa. vWF also performs hemostatic functions (3-5). In a high shear-stressed environment, vWF undergoes conformational change to expose a binding site for glycoprotein Ibα. As a result, vWF facilitates aggregation of platelets. In addition to platelet binding, vWF binds coagulation factor VIII to increase the lifetime of FVIII in plasma. The purified rhvWF-A2 contains the A2 domain of vWF.

**References**: